8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
10-Q - Catheter Precision, Inc. (0001716621) (Filer)
NT 10-Q - Catheter Precision, Inc. (0001716621) (Filer)
10-K/A - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
10-K - Catheter Precision, Inc. (0001716621) (Filer)
DEFA14A - Catheter Precision, Inc. (0001716621) (Filer)
Fastest customizable press release news feed in the world
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
ATLANTA, June 08, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), focused on making private aviation more accessible and flexible for modern travelers, today announced that it has made a strategic investment in Volato Group, Inc. (NYSE:SOAR). As part of the transaction, VTAK acquired approximately 2.9 million shares of SOAR and will own approximately 7.5% of the company's outstanding common stock. This investment provides a basis to explore potential future collaboration to improve access, efficiency, and innovation across private aviation. "This strategic investment represents an exciting opportunity for both organizations,"
Investment strengthens balance sheet as Company evaluates non-binding AI infrastructure and technology transaction opportunities Volato Group, Inc. (NYSE:SOAR) (the "Company" or "Volato"), a technology company focused on building scalable software and data solutions that improve the reliability and intelligence of high-stakes business decisions, today announced the signing of a definitive agreement to obtain a $2.2 million strategic investment lead by Catheter Precision, Inc. (NYSE:VTAK), and other institutional investors with experience investing in artificial intelligence and emerging technology companies. The investment of restricted common stock will strengthen Volato's balance shee
Company Deploys Scalable Short-Haul Model Following Kentucky Derby to Monetize Peak Travel Window Flagship Routes from NYC, Boston, DC, and Philadelphia Positioned to Drive Immediate Revenue, High Utilization, and Dense Flight Activity NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the positioning of aircraft across the Northeast to support increased travel demand this coming weekend in anticipation of the Preakness Stakes on Saturday, May 16th. The program centers on Baltimore/Washington International Airport (BWI), the primary access point for race attendees, wit
FORT MILL, SC, May 04, 2026 (GLOBE NEWSWIRE) -- — Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced increased flight capacity and the launch of a targeted hiring initiative following the shutdown of Spirit Airlines, which ceased operations on May 2, 2026 after failing to secure funding. Spirit Airlines' abrupt exit has led to widespread flight cancellations, impacted approximately 17,000 employees of which over 2,400 were pilots, and stranded passengers nationwide, marking one of the largest U.S. airline disruptions in recent decades. The disruption has reduced available capacity across key domestic routes, cont
Positioned to Meet Accelerating Travel Activity across New York City, The Hamptons, Nantucket and Martha's Vineyard Scalable Short-Haul Luxury Aviation Platform Targeting Key Regional Travel Markets FORT MILL, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the expansion of its Cirrus Vision Jet fleet ahead of peak summer demand, scaling short-haul service from New York City to East Hampton, Nantucket, Martha's Vineyard, Newport, and Cape Cod. The expansion targets one of the most concentrated luxury travel corridors in the United States, a set of routes where trips th
FORT MILL, S.C., April 21, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for key claims covering its proprietary surgical vessel closing pressure device, marking a significant milestone in the Company's intellectual property strategy. Following a rigorous examination process, the USPTO confirmed the novelty and patentability of VTAK's technology over existing prior art. The allowed claims provide protection across both the core device architecture and its method of use, creating a comprehensive and defensible intellectual property position around a foundational compo
Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as Industry Economics Continue to Shift FORT MILL, S.C., April 20, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), today announced it is accelerating expansion in short-haul markets as major global airlines rapidly retreat from regional routes amid rising fuel costs, operational constraints, and shifting route economics. This pullback reflects a structural shift, creating a sustained opportunity for high-frequency regio
Transaction Delivers Fully Consolidated, Revenue-Generating, Aviation Business with Accelerating Growth Positions VTAK for Scalable Expansion in Regional Air Mobility Ahead of eVTOL Commercialization FORT MILL, S.C., April 16, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced it received shareholder approval on April 15th of the definitive agreement to acquire Fly Flyte, Inc. ("Flyte") executed on March 9. The March 9th transaction establishes Flyte as a wholly owned operating subsidiary, delivering immediate consolidation of revenue, assets, and operating performance into VTAK. Full Ownership, Consolidated Revenue and Immediate Operating Exposure Flyte ope
FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal. The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence. The accepted manuscript titled "Accuracy of a
FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026. EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right. Davi
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
Live finance-specific insights
Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr
Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th
FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i
FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023.Highlights of the third quarter include the following: Received approval for first purchase in France. VIVO is now active in six European countries. Completed enrollment of Phase I LockeT study in excess of 100 patients. Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT. Finalized n
FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023.Highlights of the second quarter include the following:US sales team was assembled, trained, and is creating a pipeline.Additional US clinical personnel were onboarded and trained.Completion of enrollment of 125 patient VIVO patient Registry. Follow-up data is expected to be completed in June 2024.Key VIVO accounts continue to be established in both the US and Europe.Initiation of first L
This live feed shows all institutional transactions in real time.
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13G - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D - Catheter Precision, Inc. (0001716621) (Subject)
Live Leadership Updates
FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund
FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh